This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
The genus Larrea (Zygophyllaceae) has a long history of ethnobotanical use by native people of south America. The genus comprises six species: Larrea ameghinoi, Larrea cuneifolia, Larrea divaricata, Larrea mexicana, Larrea nitida and Larrea tridentate. These plants have been used to treat a variety of illnesses, including cancer, infl ammation and menstrual pain (Brent, 1999) . The extract of Larrea divaricata, a species in the Larrea genus, has a biphasic effect on cell proliferation, exerting a stimulatory effect at low concentrations but inhibiting the proliferation of BW 5147 T lymphoma cells at high concentrations (Anesini et al., 1999) . Methanolic extract of Larrea divaricata exhibited anti-tumor activity in the MCF-7 human breast adenocarcinoma cell line (Bongiovanni et al., 2008) . As a folk remedy, the genus Larrea was not recommended for pregnant and lactating females, suggesting that the Larrea genus regulates hormonal functions in females. Estrogen, a major female hormone, regulates various physiological responses in many target tissues and plays important roles in the development and progression of breast and endometrial cancers (Hayashi et al., 2003; Bryant et al., 2005) .
Estrogen exerts its biological effects by binding to estrogen receptors (ERs), which are present mainly in the nucleus and comprise ERα and ERβ (Hayashi and Yamaguchi, 2008) . Selective ER modulators (SERMs) bind to ERs and exert agonistic actions in several target tissues, while acting as ER antagonists in others (Shang and Brown, 2002) . Progesterone (P4)
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Biomol Ther 22(4), 347-354 (2014) http://dx.doi.org/10.4062/biomolther.2014.050 bound to the progesterone receptor (PR) is important in mammary gland and reproductive tract development, especially in the uterus and ovaries (Graham and Clarke, 1997; Mulac-Jericevic et al., 2003) . PR has two predominant isoforms, PR-A and PR-B. PR-B mediates the proliferative effect of P4 in the mammary gland and PR-A is essential for the functional response of P4 in the uterus and ovaries (Mulac-Jericevic et al., 2003) . Therefore, Kuhl and Stevenson suggested that the regulators of PR or ER are used for the prevention and treatment of breast cancer and postmenopausal osteoporosis (Kuhl and Stevenson, 2006) . Phytoestrogens are compounds naturally found in plants that possess estrogenic properties associated with the prevention of cancer, heart disease, menopausal symptoms and osteoporosis (Bedell et al., 2014) . The main classes of phytoestrogens in terms of chemical structure are isofl avones, prenylated fl avonoids, coumestans, and lignans (Ward and Kuhnle, 2010) .
Phytochemical studies have indicated that the genus Larrea contains lignans, fl avonoids, condensed tannins, triterpene saponins and naphthoquinones with lignans being the major component (Gisvold and Thaker, 1974; Konno et al., 1990) . Although various species of the genus Larrea have been studied to have therapeutic effects, pharmacological properties of Larrea nitida associated female hormones and their interaction with hormone receptors have not reported.
In this study, we evaluated the SERM activity of Larrea nitida to determine its pharmacological importance as a source of phytoestrogens. Extract of Larrea nitida (LNE) was investigated in terms of its ability to bind to purifi ed hERα and hERβ, and to modulate ER-mediated gene transcription, proliferation in MCF-7 breast cancer cells, and its uterotrophic effect in rats.
MATERIALS AND METHODS

Cell culture and materials
The MCF-7 cell line is a steroid-sensitive subline developed from MCF-7 human breast cancer cells (kindly provided by Dr. Anna Soto, Tufts University, Boston, MA, USA). MCF-7 cells were cultured in Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic-antimycotic solution. Cells were maintained in humidifi ed 5% CO 2 atmosphere at 37 o C. All cell culture reagents were purchased from Gibco (Carlsbad, CA, USA). [2,4,6,7- 3 H]-17β-Estradiol ([ 3 H]-E2, 88.0 Ci/mmol) was purchased from PerkinElmer Inc. (Boston, MA, USA). Reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) and unless stated otherwise, were of research grade suitable for cell culture or of the highest grade available. Each chemical was dissolved in either ethanol or DMSO before being tested in the various assay systems. Stock solutions were stored at -20 o C. The fi nal solvent concentration in the culture medium did not exceed 0.5%.
Plant materials
The stems and leaves of Larrea nitida were collected in Jarilla, Chile in 2007 and identifi ed by Dr. Joongku Lee, Korea Research Institute of Bioscience and Biotechnology (KRIBB). A voucher specimen (access number FBM026-052) was deposited in the herbarium of the KRIBB. (Son et al., 2005) .
Preparation of LNE and its chromatography profi le
Cell proliferation assay
MCF-7 cells were plated in 12-well plates at an initial density of 6×10 4 per well (Soto and Sonnenschein, 1984; Soto and Sonnenschein, 1985) . Cells were allowed to attach for 24 h and the medium was then replaced with experimental medium (phenol red-free DMEM containing 5% charcoal dextrantreated FBS (CD-FBS)). LNE, E2, ICI 182,780 (ICI; pure ER antagonist), or a combination of these compounds was added to the medium in a range of concentrations and the cells were incubated for 6 days (late exponential phase). Cell growth was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.
ERE-luciferase reporter gene assay
MCF-7 cells were seeded in 12-well plates (6×10 5 cells/ well) and cultured in phenol red-free DMEM containing 5% CD-FBS in triplicate. Cells were then transiently transfected with pERE-Luc plasmid (0.5 μg/well) and 0.2 μg of an inactive control plasmid encoding a β-galactosidase gene using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA). The pERE-Luc plasmid contains three copies of the Xenopus laevis vitellogenin A2 ERE upstream of fi refl y luciferase (a gift from Dr. V. C. Jordan, Lombardi Comprehensive Cancer Center, Georgetown University) (Catherino and Jordan, 1995) . One day after transfection, various concentrations of LNE were added in the presence or absence of E2. Cells were lysed for luciferase activity analysis after incubation for 24 h. Luciferase activity was measured using a luciferase reporter assay system (Promega, Madison, WI, USA). Luminescence was detected with a TD-20/20 luminometer (Turner Design, Sunnyvale, CA, USA). Finally, luciferase activities were normalized to β-galactosidase activity.
ER ligand-binding assay
The binding ability of the test compound to control or tre ated recombinant full-length human estrogen receptor α (hERα) was assessed as described previously (Obourn et al., 1993) . hERα (2088 pmol/mg estrogen binding activity, Invitrogen Corp.) was diluted to a concentration of 5 nM with a binding buffer containing 10 mM Tris (pH 7.5), 10% glycerol, 1 mM DTT and 1 mg/ml bovine serum albumin (BSA). The hERα was labeled with [
3 H]-E2 (3 nM) in the presence or absence of 10 -6 M unlabeled E2, various concentration of LNE or LNs fractions. For the hERβ binding assay, hERβ (4500 pmol/mg estrogen binding activity, Invitrogen Corp.) was diluted to a concentration of 10 nM with the binding buffer and labeled with [ 3 H]-E2 (10 nM) in the presence or absence of 10 -6 M unlabeled E2, LNE or LNs. After incubation for 2 h at 27 o C, the reactions were terminated by rapid fi ltration through glass-fi ber fi lters (Packard www.biomolther.org Instrument B.V. Chemical Operations) presoaked with ice-cold 0.05% polyethylenimine using a PerkinElmer Filter Mate Harvester. The fi lters were washed fi ve times with ice-cold buffer, dried, and then placed in scintillation vials containing 3 ml of Packard Ultima Gold scintillation cocktail. After shaking and overnight equilibration of the vials, the radioactivity trapped on each fi lter was measured using a Packard 2000CA liquid scintillation counter. Non-specifi c [
3 H]-E2 binding was determined in the presence of 10 -6 M unlabeled E2. The specifi c binding percent for each ER was determined as follows: [(dpm sample -dpm nonspecifi c )/(dpm control -dpm nonspecifi c )]×100. Relative binding affinity (RBA) was calculated as follows: RBA= [IC 50 (E2) /IC 50 (LNE or LNs) ]×100. The fi nal results for each treatment condition were expressed as means ± standard error (SE).
Uterotrophic assay
All animal studies were performed in accordance with the guidelines provided by the Korean Food and Drug Administration. The study protocol was reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of Sookmyung Women's University. LNE was tested in vivo to determine its ability to induce uterine wet weight gain in rats. Immature female Sprague-Dawley rats (20-21 days old) with body weights ranging from 38-48 g were obtained from the Samtaco Animal Farm (Osan, Korea) and were housed under standard animal laboratory conditions with food and water available ad libitum. The light/dark cycle was 12-h light/12-h dark, with dark cycle starting at 21:00 h. Animals were randomly divided into four groups, with the group body weights within 10% of the population mean. Animals were subcutaneously injected once daily for a period of 3 days with (i) corn oil alone (vehicle control); (ii) E2 (0.003 mg/kg; positive control); or (iii) LNE (100 or 500 mg/kg). Each treatment group consisted of fi ve animals. On day 4, the animals were weighed and euthanized (24 h following the last treatment). The uteri were quickly removed and the connective tissue was excised. The uteri were then nicked, blotted and weighed. The effects of LNE on uterus wet weight were determined by reporting absolute uterine weights and uterine wet weights normalized for the rats' respective body weights.
Statistical analysis
Data are expressed as means ± standard error (SE). Comparisons between groups were performed by one-way analysis of variance (ANOVA) with appropriate Bonferroni tests using the GraphPad Prism Software (San Diego, CA, USA). A p-value less than 0.05 was considered to indicate statistical signifi cance.
RESULTS
Eff ect of LNE on MCF-7 cell proliferation
The MCF-7 cell proliferation assay evaluates the cellular response to either estrogenic or antiestrogenic compound in ER-mediated pathway. LNE was investigated for their ability to enhance the proliferation of estrogen-dependent MCF-7 breast cancer cell. E2 and ICI were used as a positive control (an ER agonist) and a negative control (an ER antagonist), respectively in estrogen-derived cell proliferation in MCF-7 cell. The cells were treated with the extracts of LNE (10 -7 -10 -5 g/ml), ICI (10 -6 M), E2 (10 -10 M), or the LNE in combination with E2 for 6 days and the proliferative effects were evaluated using MTT assay. As shown in Fig. 1 , treatment of cells with LNE resulted in dose-dependent increases of cell growth in MCF-7 cells. Further investigation was conducted to test whether the cell proliferation was associated with the function of ER, the effects of co-treatment of the LNE with E2 on MCF-7 cell proliferation was examined. Interestingly, the LNE dose-dependently reduced cell growth caused by E2 (10 -10 M) compared to E2 alone. Our investigation indicated that only LNE standalone treatment has a proliferative effect via ER, whereas LNE inhibited MCF-7 cell proliferation induced by E2. These data suggested that LNE has both estrogenic and anti-estrogenic effect in the absence or presence of E2 in MCF-7 cell.
Estrogenic eff ect in ERE mediated gene transcription
LNE was tested for the transcriptional activity via classical ER signaling pathway in MCF-7 cell. The cells were transfect- ed with the plasmid containing the ERE in the promoter region of the luciferase reporter gene (pERE-Luc). Fig. 2 demonstrated the effect of LNE (10 -8 -10 -6 g/ml), E2 (10 -10 M), and ICI (10 -6 M) on luciferase activity in MCF-7 cell transfected with pERELuc. The results showed that E2 treatment induced 7-fold of luciferase gene expression compared to the vehicle control and LNE induced gene expression by 2-fold, which was not signifi cant compared to E2 and much weaker than that of E2. Further investigation was conducted to test whether LNE was involved in the transcriptional activation of ERE-luciferase by E2. However, LNE did not inhibit the E2-induced luciferase in MCF-7 cell at any concentrations tested in this study. The known ER pure antagonist, ICI completely inhibited E2-induced luciferase activity, implying that luciferase induction was mediated via ER function. Our results showed that LNE possessed weak estrogenic activity in the absence of E2 in MCF-7 cells. However, a combination of LNE with E2 did not affect the E2-mediated transcriptional activity in the same cell line, which was different to what has been observed in MCF-7 cell proliferation experiment.
Fractions of LNE and chromatographic isolation of LNs fractions
To identify the bioactive constituents responsible for the SERM effi cacy, fi rst, we fractionated LNE using a reversedphase silica column chromatography by eluting with a gradient mixture of H 2 O-MeOH (90:10-0:100). Based on this separation, LNE constituents were resolved into 16 fractions (LN01-16) (Fig. 3A) . Nordihydroguaiaretic acid (NDGA) was identifi ed as one of active compounds by NMR in the LNE (Fig. 3B) .
Competitive binding affi nities of LNE and LNs to ERα and ERβ
LNE and LN 01-16 fractions were tested for their ability to bind ERs. The binding affi nities of the LNE and LNs as hER ligands were determined its ability to displace [ 3 H]-E2 bound to the receptor from either hERα or hERβ using [
3 H]-E2 and recombinant purifi ed ERs. The binding affi nities were expressed as RBA values with the relative binding of the E2 standard set to 100. As expected, the ER binding assay showed strong affi nities for E2 with IC 50 of 1.2×10 -9 g/ml and 2.5×10 -9 g/ml for the hERα and the hERβ, respectively (Table 1) . LNE showed high binding affi nities for the hERα and hERβ with the values of IC 50 of 1.2×10 -7 g/ml for hERα and 1.0×10 -7 g/ml for hERβ, respectively. LN01-16, fractions 1-16 were also tested for their binding affi nities to hERα and hERβ. Among the 16 fractions, LN08, LN09, LN10, LN11 and LN12 were active in the IC 50 range of 0.38×10 -6 g /ml and IC 50 of 20.08×10 -6 g /ml (Table 1) . The IC 50 values of LN08 for hERα and hERβ were 1.1×10 -6 and 5.3×10 -7 g/ml, respectively. LN10 also showed high binding affi nity to hERα and hERβ, with IC 50 values of 3.8×10 -7 and 3.18×10 -6 g/ml, respectively. It showed that LN08 and LN10 had more potent affi nities for binding on both hER α and β than other fractions. RBA showed that the affi nities of LNE and LN08 have selectivity for hERβ rather than hERα. Consequently, we suggest that LNE may have the potential to preferentially target hERβ over hERα in cells or in animals.
Atrophic eff ect on uterine of immature rats
An in vivo rodent uterine bioassay was developed in which an estrogen-induced uterotrophic response was estimated as an increase in uterine tissue mass in immature rodents. LNE was tested in vivo to determine its ability to induce uterine weight gain in rats. There was no signifi cant difference of initial body weights among the rats in each group. The changes of body weight, calculated by subtraction of the body weight at 1 day before administration from that on the day after the last injection, are shown in Table 2 . The positive agent E2 (0.003 mg/kg) increased uterine wet weights when rats were administered with E2 via the subcutaneous injection route. As shown in Table. 2, uterine wet weight was increased 1.8-fold following treatment with 0.003 mg/kg of E2 compared to vehicle group. However, the uteri of rats treated with 100 and 500 mg/kg of LNE were signifi cantly atrophied compared to those of vehicle control rats (Table 2 ). In addition, rats administered with LNE (100 and 500 mg/kg) showed body weight gains of a few grams compared to control group and E2 treatment group. www.biomolther.org
Anti-proliferative eff ect of LNE
LNE reduced uterine weights in immature uterotrophic assay and showed weight gains after treatment with the LNE for 3 days (Fig. 4A, Table 2 ). We hypothesized that this weight gain effect of LNE is attributed to its properties of progesterone. Therefore, we examined the effects of LNE on expression of PR-A, PR-B, and ERα proteins in rats. Steady-state protein levels were measured by Western blot analysis, as Fig. 4 . LNE reduced wet weight and protein expression of estrogen responsive genes in immature rats. Each compound was administered subcutaneously at the indicated concentration (100 mg and 500 mg/kg/day) for 3 days. (A) Administration of LNE reduced the uterine wet weights in immature rat uterotrophic assay. (B) Whole cell proteins from uterus were extracted and analyzed for the expression of ERα, PR-A, and PR-B by Western blot analysis. ERα, PR-A and PR-B protein levels were signifi cantly decreased in the LNE-treated uterus. Equal loading of protein in each lane was confi rmed by β-actin as a loading control. Values signifi cantly different from vehicle group are indicated by asterisk: (***p<0.001, **p<0.01, *p<0.05). Fig. 4B . ERα protein levels in the uterine tissues were down regulated after treatments with 0.003 mg/kg of E2. It is known that E2 downregulates ERα protein levels in MCF-7 cells, which is consistent with our result in uterus (Gierthy et al., 1996; Park et al., 2009) . The 100 or 500 mg/kg of LNE signifi cantly reduced the expression of ERα, PR-A and PR-B, compared with that of the E2-treated group in uterus (Fig. 4B ). These data suggested that LNE may interact with the ER as well as modulate the expression levels of ER and PR.
DISCUSSION
The lives of women suffered from breast cancer have probably been saved because of the anti-proliferative effects of tamoxifen as a representative SERM on mammary epithelial cells. However use of SERM is limited because of undesirable tissue-specifi c effects such as thromboembolic events, strokes, and uterine cancer (Wysowski et al., 2002) . Therefore phytoestrogens (plant SERMs) are gaining importance for the relief of acute women's diseases due to their therapeutic effi cacy and low risk of developing potential side effects.
Larrea plant has a long history of use with the Native Americans and European settlers in the south-western deserts of the United States. It has been used for menstrual pain, however lactating women were not recommended to take products of Larrea tridentate, implying that the genus Larrea regulate women's hormonal actions. Although Larrea nitida has been used in South America as a traditional medicine for the women, therapeutic effects of Larrea tridentate on women's diseases and its mechanism of action have yet not been investigated.
The objective of our study was to investigate the potential estrogenic activity of LNE in breast cancer cell and uterine tissue, which may lead to development of SERM remedy. LNE induced cellular proliferation in MCF-7 cells in a dose-dependent fashion (Fig. 1) . However, LNE inhibited E2-induced proliferation in the same cell line. Our data imply that LNE has properties of a partial agonist and mixed antagonist to ER depending on the level of endogenous estrogen. Estrogenic activity was also detected by measuring the activity of ERE-dependent reporter gene transcription in cells transiently transfected with pERE-Luc plasmid. LNE induced gene expression of EREdependent luciferase in MCF-7 cells, however, E2-induced gene activation was not affected by co-treatment of LNE (Fig.  2) . The inconsistency in inhibitory effects of LNE on the E2-induced cell proliferation and ERE-dependent reporter gene expression implies that the molecular mechanisms by which MCF-7 cell proliferation may be mediated by alternative ERmediated signaling pathways in addition to an event including classical ER-ERE pathway (Smith and O'Malley, 2004) . Furthermore, it is possible that LNE contains various phytoestrogen chemicals, some of which are responsible for ER agonist actions and others for ER antagonistic function leading to both estrogenic action in classical ER signaling pathway and antiestrogenic action on E2-induced MCF-7 cell proliferation. Thus, it seems worth to isolate and identify individual phytoestrogenic compounds from LNE, which would serve as the direct ER agonist or the lead to develop a better SERM.
Phytochemical studies that were carried out on Larrea tridentate isolated and identifi ed lignans such as NDGA and triterpenes (Abou-Gazar et al., 2004; Jitsuno and Mimaki, 2010) . www.biomolther.org NDGA found in the Larrea tridentate had binding affi nities for ERα and β with IC 50 of 30 μM (Fujimoto et al., 2004) . To trace the bioactive constituents responsible for the SERM effi cacy of LNE, chromatographic analysis and NMR were performed (Fig. 3) . LNE constituents were resolved into 16 fractions that were tested for their abilities to bind both ER α and β. Among sixteen fractions, LN08 and LN10 had more potent affi nities for binding on hER α and β than other fractions, which would guide to next isolation of single compounds and their structural elucidation (Table 1 ). In the present study, we suggest that NDGA is partially responsible for SERM activity of LNE.
LNE and LN08 possessed higher binding affi nity to hERβ than hERα. In human breast cancers, ERα is expressed as approximately 70% of breast tumor, but ERβ expression is lost during breast cancer progression, most likely due to promoter methylation (Skliris et al., 2008) . Furthermore, clinical studies suggested that the signaling of ERβ in breast tumors increases the effectiveness of tamoxifen therapy (Honma et al., 2008) . It is expected that higher binding affi nity toward hERβ than hERα of LNE and LN8 is of clinical value in breast cancer therapy.
Furthermore, LNE had uterine atrophic effect, even at 100 or 500 mg/kg, suggesting that LNE possesses a SERMlike effect via action of ER antagonist in rat uterus ( Table 2) . The protein expression levels of PR-A and PR-B were down regulated after 3 days treatment with LNE compared with the vehicle (Fig. 4) . PR-A has been shown to be a dominant inhibitor of the transcriptional activity of PR-B (Wen et al., 1994; Giangrande and McDonnell, 1999) . It was reported that PR-A regulates the activity of a number of nuclear receptors, including the ERs and glucocorticoid receptor (Wen et al., 1994) . We showed that the LNE reduced the PR expression in the uterus of rats, suggesting that the modulation of PR expression and thus function by LNE may be responsible for uterine atrophy and weight gain observed in immature rats treated with LNE.
Our data indicated that selectively targeting ERβ and PR by LNE may function as a potential suppressor of women's cancer that promotes differentiation and inhibits ERα-mediated pro liferation. Since the fi rst endocrine agent tamoxifen was described in 1986, tamoxifen as the standard endocrine the -rapy has been shown to reduce ER-positive breast cancer. How ever more recent studies are suggesting the positive roles of naturally occurring SERM such as a phytoestrogen as an alternative therapeutic option to circumvent increased risks of tamoxifen. Results from the studies of naturally-occurring SERM both in cell culture and in animals have provided insights into new dimension of the complex nature of ER action in health and disease.
In summary, our results showed that LNE and LN08 had selective binding affi nity to hERβ rather than hERα and treatment of LNE reduced the cell proliferation in the presence of endogenous estrogen. LNE had uterine atrophic effects in immature rats through reducing the expression of ER/PR proteins (Fig. 5) . It suggested that LNE and its bioactive principles may act as SERMs or SPRMs via ER and/or PR in female hormone-responsive organs.
In conclusion, our present study provided the fi rst evidence for phytoestrogenic properties of LNE and its potential application as a hormonal therapy for women's disease. Further in vitro and in vivo studies and characterization of the active components of LNE will shed light on its health-promoting effects and suitability in hormone-dependent women's disease.
